Keeping an Eye Out: Emerging Trends in the Management of Metastatic Uveal Melanoma

EXPERT INTERVIEWCME

Author(s)/Faculty: Alexander N. Shoushtari, MD; Prof. Dr. med. Jessica C. Hassel
Release Date: 12/22/2021	Expiration Date: 12/21/2022
Credit Type: CME	Number of Credits: 0.75
Content Type: Lecture	Provider:
Uveal melanoma is the most common ocular cancer, typically affecting older patients, particularly men. It is associated with a high mortality rate, especially after metastases. Individuals with fair skin and eyes are more susceptible to the disease due to a lower amount of melanin. Diagnosing uveal melanoma is challenging, as only approximately 30% of patients experience symptoms such as secondary glaucoma and changes in iris color and pupil shape, thus misdiagnosis is common. The current standard of care for uveal melanoma includes enucleation, globe-preserving therapies, or radiotherapy, but the rates of metastases remain high. Ongoing research has yielded a greater understanding of the disease mechanisms, which has led to advances in biomarkers and therapies. However, given the novelty of these studies, as well as the disease mechanisms that differ from other skin cancers, oncology providers need timely education on these topics to remain current. In this educational activity, expert faculty review the most recent data regarding the molecular basis of uveal melanoma and the clinical data supporting the use of new and emerging therapies. They also explore the potential role of novel therapies in the current treatment algorithm for uveal melanoma.

Overview